Evgeny Zaytsev - 19 Aug 2026 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Reporting relationship: Director
Issuer ticker: CALC
Reported as of: 19 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Aug 2026, 18:44:49 UTC
Prior SEC filing: 07 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ John Dunn, Attorney-in-Fact

Key filing fact

Evgeny Zaytsev filed Form 4 for CalciMedica, Inc. (CALC) on 21 Aug 2026.

Key facts

This page summarizes Evgeny Zaytsev's Form 4 filing for CalciMedica, Inc. (CALC).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 21 Aug 2026, 18:44.

Change

Previous filing in this sequence was filed on 07 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001674797 Primary reporting owner

Zaytsev Evgeny

Relationship: Director
Address: C/O CALCIMEDICA, INC., 505 COAST S. BLVD, SUITE 300-9, LA JOLLA
Signature: /s/ John Dunn, Attorney-in-Fact
Signature date: 21 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CALC transaction Derivative

Warrant

Award

Transaction value
Shares: +1,450,267
Change %
Price: $0.000000^*
Shares after: 1,450,267
Date: 19 Aug 2026
Ownership: By Bering Partners II, L.P.
Underlying class: Common Stock
Underlying amount: 1,450,267
Exercise price: $0.8033
Footnotes: F1, F2, F3

CALC transaction Derivative

Warrant

Award

Transaction value
Shares: +1,450,267
Change %
Price: $0.000000^*
Shares after: 1,450,267
Date: 19 Aug 2026
Ownership: By Bering Partners II, L.P.
Underlying class: Common Stock
Underlying amount: 1,450,267
Exercise price: $1.00
Footnotes: F1, F3, F4

CALC transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
Shares: +10,000
Change %
Price: $0.000000^*
Shares after: 10,000
Date: 19 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $0.6131
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

Footnote F2

The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

Footnote F3

The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein.

Footnote F4

The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

Footnote F5

1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.